Accelerating Drug Discovery for FTD
Funds research to optimize and test innovative drug therapies for frontotemporal degeneration, focusing on lead compound refinement and in vivo efficacy studies.
Funder: The Association for Frontotemporal Degeneration
Due Dates: May 11, 2026 (Letter of Intent) | July 20, 2026 (Invited Full Proposal, 5:00 pm ET)
Funding Amounts: $300,000–$350,000 for 1 year; larger budgets considered with prior approval; follow-on funding possible.
Summary: Supports development and optimization of innovative therapies for frontotemporal degeneration, focusing on lead compound refinement and in vivo testing.
Description
This program, jointly offered by The Association for Frontotemporal Degeneration (AFTD) and the Alzheimer’s Drug Discovery Foundation (ADDF), aims to accelerate drug discovery for frontotemporal degeneration (FTD). The initiative funds the development and optimization of small molecule and biologic therapies, such as antibodies, oligonucleotides, peptides, and gene therapies. Key priorities include lead optimization of novel disease-modifying compounds and in vivo testing of new or repurposed drug candidates in relevant animal models to assess pharmacokinetics, target engagement, efficacy, and preliminary tolerability. The program does not support target identification, assay development, or high-throughput screening.
